Navigation Links
WaferGen to Present at the Seventh Annual BIO Investor Forum
Date:10/23/2008

FREMONT, Calif., Oct. 23 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today announced that Alnoor Shivji, WaferGen's president and chief executive officer, will deliver a corporate presentation at the Seventh Annual BIO Investor Forum. The conference will be held October 28-31, 2008, at the Palace Hotel in San Francisco

WaferGen's presentation will take place at 11:30 a.m. (PST) on Thursday, October 30, 2008. The presentation will include an overview of the company's SmartChip(TM) Real-Time PCR System, which is currently being developed for the gene expression and genotyping markets, and the SmartSlide(TM) Micro- Incubation System that WaferGen is actively marketing. A live webcast and 90- day archived presentation can be accessed at http://www.wafergen.com.

About WaferGen

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker discovery and validation. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide, which was launched in 2006, represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research. Representative SmartSlide customers include Harvard University, Mayo Clinic, California Institute of Technology (CalTech), Abbott Labs, and the National Institutes of Health (NIH).

Contact:

Vida Communication (on behalf of WaferGen)

Stephanie Diaz (investors) Tim Brons (media)

415-675-7400 415-675-7402

sdiaz@vidacommunication.com tbrons@vidacommunication.com


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen Announces Second Quarter 2008 Financial Results
2. WaferGen to Present at the Ninth Annual Beyond Genome Conference
3. WaferGen Announces Signing of Two Private Placements
4. WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference
5. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
6. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
7. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
8. WaferGen Announces Management Team Promotions
9. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
10. WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. Vical to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):